CRISPR editing as a therapeutic strategy for Duchenne muscular dystrophy-anti-Cas9 immune response casts its shadow over safety and efficacy.
Gene therapy, 29(10-11): 575-577 PMID 35194186 DOI 10.1038/s41434-022-00323-8
Abstract
This article has no abstract in PubMed.